Comparative Pharmacology
Head-to-head clinical analysis: NIPRIDE versus PRISCOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIPRIDE versus PRISCOLINE.
NIPRIDE vs PRISCOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nipride (sodium nitroprusside) is a potent vasodilator that acts directly on vascular smooth muscle, both arterial and venous, by releasing nitric oxide (NO). Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, leading to relaxation of smooth muscle and subsequent reduction in peripheral vascular resistance and blood pressure.
Priscoline (tolazoline) is a competitive alpha-adrenergic receptor antagonist; also has direct vasodilatory and histamine-like effects, leading to peripheral vasodilation and decreased peripheral vascular resistance.
Intravenous infusion: initial 0.3-0.5 mcg/kg/min, titrate up to 10 mcg/kg/min as needed.
10-50 mg subcutaneously or intramuscularly every 4-6 hours; intravenous administration (10 mg slow IV push) reserved for acute vasospastic episodes.
None Documented
None Documented
Nitroprusside: ~2 minutes (converted to cyanide); cyanide (as thiocyanate): 2.7 days; clinical context: continuous IV infusion required; thiocyanate accumulation risk in renal impairment.
Terminal elimination half-life is approximately 3-4 hours in adults; prolonged in renal impairment.
Renal: ~50% as unchanged drug; hepatic metabolism to thiocyanate, which is renally eliminated (half-life 2-3 days); <1% fecal.
Primarily renal excretion of unchanged drug (approximately 90%); minor fecal excretion (<10%).
Category C
Category C
Vasodilator
Vasodilator